In May 2005, the FDA approved the first vaccine for adolescents that provides a booster immunization against whooping cough (pertussis) in combination with tetanus and diphtheria.
Boostrix, a tetanus toxoid (T), reduced diphtheria toxoid (d), and acellular pertussis vaccine (ap) absorbed, will be marketed by GlaxoSmithKline of Philadelphia. Although booster vaccines for adolescents containing T and d are currently licensed and marketed for use in this age group, none contain a pertussis component. Boostrix is indicated for use as a single booster dose to adolescents ages 10 to 18.
Adolescents who received Boostrix experienced pain, redness, and swelling at the injection site. The frequency of redness and swelling after Boostrix was similar to what is expected after the administration of a Td vaccine. Pain reactions at the injection site, however, were more frequent with those who received Boostrix. Other side effects included headaches, fever, and fatigue for a short period of time after injection.
COPYRIGHT 2005 U.S. Government Printing Office
COPYRIGHT 2008 Gale, Cengage Learning
Boostrix, a tetanus toxoid (T), reduced diphtheria toxoid (d), and acellular pertussis vaccine (ap) absorbed, will be marketed by GlaxoSmithKline of Philadelphia. Although booster vaccines for adolescents containing T and d are currently licensed and marketed for use in this age group, none contain a pertussis component. Boostrix is indicated for use as a single booster dose to adolescents ages 10 to 18.
Adolescents who received Boostrix experienced pain, redness, and swelling at the injection site. The frequency of redness and swelling after Boostrix was similar to what is expected after the administration of a Td vaccine. Pain reactions at the injection site, however, were more frequent with those who received Boostrix. Other side effects included headaches, fever, and fatigue for a short period of time after injection.
COPYRIGHT 2005 U.S. Government Printing Office
COPYRIGHT 2008 Gale, Cengage Learning
No comments:
Post a Comment